医学と薬学　79/8　2022年8月号

出版社： 自然科学社
発行日： 2022-07-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 関節リウマチ治療の最前線
電子書籍版： 2022-07-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　関節リウマチ治療の最前線

    序文―治療の新たな潮流
    関節リウマチの治療
    メトトレキサート
    生物学的製剤
    JAK阻害薬
    薬剤の副作用に対する対策と治療
    合併症・随伴症の管理と治療

    Diagnosis
    　新しいノロウイルス抗原検査キット『クイックナビ™-ノロ3』の評価
    　マイコプラズマ抗原検出試薬「ラピッドテスタMyco」の臨床評価
    　cAMPバイオセンサおよびヒトTSH受容体共発現細胞を用いた
    　　新規TSAb測定試薬バイオセンサTSAb「ヤマサ」の基礎的検討
    　cAMPバイオセンサおよびヒトTSH受容体共発現細胞を用いた
    　　新規TSAb測定試薬バイオセンサTSAb「ヤマサ」の臨床評価
    　便検体および便培養コロニーを用いたClostridioides difficile抗原迅速診断キット
    　 「クイックチェイサー® CD GDH/TOX」の有用性に関する評価
    ルミパルスL2400を用いた全自動タクロリムス定量試薬
    　「ルミパルスプレストiTACTタクロリムス」の基礎性能評価

    症例報告
    ヒト臍帯血幹細胞培養上清液を用いた創傷治癒に関する症例報告

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 関節リウマチ治療の最前線】

P.1022 掲載の参考文献
1) Firestein GS, Budd RC, Gabriel SE, et al : Kelly's text book of Rheumatology Ninth Edition. Elsevier Saunders, Philadelphia, 2012.
 
2) McInnes IB, Schett G : The pathogenesis of rheumatoid arthritis. N Engl J Med 365 : 2205-2219, 2011.
PubMed
3) Smolen JS, Aletaha D, Koeller M, et al : New therapies for treatment of rheumatoid arthritis. Lancet 370 : 1861-1874, 2007.
PubMed
4) Smolen JS, van der Heijde D, Machold KP, et al : Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73 : 3-5, 2014.
PubMed
5) Lacaille D, Avina-Zubieta JA, Sayre EC, et al : Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. Ann Rheum Dis 76 : 1057-1063, 2017.
PubMed
6) 竹内勤 : 関節リウマチ : 診断と治療法の進歩. 日本内科学会雑誌 101 : 2815-2817, 2012.
 
7) 竹内勤 : 関節リウマチ診療の軌跡と新たな潮流. 日本内科学会雑誌 109 : 1669-1684, 2020.
 
竹内勤 : 関節リウマチ. 日本内科学会雑誌 99 : 2392-2400, 2010.
 
竹内勤 : 関節リウマチの治療の進歩. 日本内科学会雑誌 101 : 647-653, 2012.
 
竹内勤 : 関節リウマチ : 診断と治療法の進歩. 日本内科学会雑誌 101 : 2815-2817, 2012.
 
竹内勤, 金子祐子 : 関節リウマチにおけるTREAT TO TARGET. 日本内科学会雑誌 103 : 2321-2327, 2014.
 
Smolen JS, Landewe R, Breedveld FC, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs, Ann Rheum Dis 69 : 964-975, 2010.
PubMed
竹内勤 : 関節リウマチの治療の最新の進歩と今後の課題. 日本内科学会雑誌 104 : 1773-1782, 2015.
 
Takeuchi T and Kameda H : The Japanese experiences with biologic therapies for Rheumatoid Arthritis. Nature Rev Rheum 6 : 644-652, 2010.
 
Burmester G, Bijlsma JWJ, Cutolo M, et al : Managing rheumatic and musculoskeletal diseases-past, present and future. Nature Rev Rheum 13 : 443-448, 2017.
 
竹内勤 : 関節リウマチの治療の最新の進歩と今後の課題. 日本内科学会雑誌 104 : 1773-1782, 2015.
 
竹内勤 : 関節リウマチ診療の軌跡と新たな潮流. 日本内科学会雑誌 109 : 1669-1684, 2020.
 
P.1025 掲載の参考文献
1) Kameda H, Fujii T, Nakajima A, et al : Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 29 : 31-40, 2019.
PubMed
2) Smolen JS, Landewe RBM, Bijlsma JWJ, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699. 2020.
PubMed
3) 日本リウマチ学会 編 : 関節リウマチ診療ガイドライン 2020, pp.20-30, 診断と治療社, 東京, 2021.
 
4) Kameda H, Amano K, Sekiguchi N, et al : Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis : a better response in male patients. Mod Rheumatol 14 : 442-446, 2004.
PubMed
5) Takahashi C, Kaneko Y, Okano Y, et al : Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis : a 76-week prospective study. RMD Open 3 : e000363, 2017.
PubMed
6) Cronstein BN, Aune TM : Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16 : 145-154, 2020.
PubMed
7) Muto S, Minamitani N, Ogura T, et al : Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis. Mod Rheumatol 31 : 1079-1086, 2021.
PubMed
8) Ibfelt EH, Jacobsen RK, Kopp TI, et al : Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis : a nationwide population-based study. Rheumatology 60 : 346-352, 2021.
PubMed
9) Juge PA, Lee JS, Lau J, et al : Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 57 : 2000337, 2021.
PubMed
10) Baecklund E, Iliadou A, Askling J, et al : Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 : 692-701, 2006.
 
11) Honda S, Sakai R, Inoue E, et al : Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis : Results from a Japanese multi-institutional retrospective study. Mod Rheumatol : 1869370, 2021.
 
12) Kuramoto N, Saito S, Fujii T, et al : Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course : A retrospective, multicenter, case control study. Mod Rheumatol : 1-16, 2021.
 
13) Braun J, Kastner P, Flaxenberg P, et al : Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trail. Arthritis Rheum 58 : 73-81, 2008.
 
14) Stamp LK, Barclay ML, O'Donnell JL, et al : Effects of change from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 38 : 2540-2547, 2011 ;
 
15) Schiff MH, Jaffe JS, Freundlich B : Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis : drug-exposure limitations of oral methotrexate at doses > 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73 : 1549-1551, 2014.
PubMed
16) Li D, Yang Z, Kang P, et al. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate : A systematic review and meta-analysis. Semin Arthritis Rheum 45 : 656-662, 2016.
PubMed
17) Li CKH, Baker K, Jones T, et al : Safety and tolerability of subcutaneous methotrexate in routine clinical practice. Arthritis Care Res 73 : 1306-1311, 2021.
PubMed
P.1037 掲載の参考文献
1) 日本リウマチ学会 編 : 関節リウマチ診療ガイドライン 2020, 診断と治療社, 東京, 2021.
 
2) 日本リウマチ学会ホームページ : 関節リウマチ (RA) に対するTNF阻害薬使用の手引き (2020年2月1日改訂版). https://www.ryumachi-jp.com/publish/guide/guideline_tnf/
 
3) 日本リウマチ学会ホームページ : 関節リウマチ (RA) に対するIL-6阻害薬使用の手引き (2020年2月1日改訂版). https://www.ryumachi-jp.com/publish/guide/guideline_il-6/
 
4) 日本リウマチ学会ホームページ : 関節リウマチ (RA) に対するアバタセプト使用の手引き (2020年2月1日改訂版). https://www.ryumachi-jp.com/publish/guide/guideline_abt/
 
5) 日本リウマチ学会ホームページ : 関節リウマチに対するデノスマブ使用の手引き. https://www.ryumachi-jp.com/publish/guide/guideline_denosumab/
 
6) 日本呼吸器学会 生物学的製剤と呼吸器疾患・診療の手引き作成委員会 編 : 生物学的製剤と呼吸器疾患診療の手引き, 2014. http://fa.jrs.or.jp/guidelines/guidance_respiratory-disease.pdf
 
7) 日本肝臓学会 編 : B型肝炎治療ガイドライン (第3.4版) 2021年5月, 資料3 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン. https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/B_v3.4.pdf
 
P.1045 掲載の参考文献
1) Traves PG, Murray B, Campigotto F, et al : JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 80 : 865-875, 2021.
PubMed
2) 木下誉富 : キナーゼを標的とした構造生物学および創薬の現状. 日本結晶学会誌 59 : 174-181, 2017.
 
3) Faquetti ML, Grisoni F, Schneider P, et al : Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection. Sci Rep 12 : 7843, 2022.
PubMed
4) Charles-Schoeman C, Fleischmann R, Mysler E, et al : The Risk of Venous Thromboembolic Events in Patients with RA Aged > 50 Years with > 1 Cardiovascular Risk Factor : Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors. Arthritis Rheumatol 73 (Suppl 10), 2021.
 
5) Ytterberg SR, Bhatt DL, Mikuls TR, et al : Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386 : 316-326, 2022.
PubMed
6) Buch M, Charles-Schoeman C, Curtis J, et al : Major adverse cardiovascular events, malignancies and venous thromboembolism by baseline cardiovascular risk : a post hoc analysis of ORAL Surveillance. Ann Rheum Dis 81 : 356, 2022.
 
7) Khosrow-Khavar F, Kim SC, Lee H, et al : Tofacitinib and risk of cardiovascular outcomes : results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 81 : 798-804, 2022.
 
8) Khosrow-Khavar F, Desai RJ, Lee H, et al : Tofacitinib and risk of malignancy : results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) Study. Arthritis Rheumatol 2022. [Online ahead of print]
 
9) Kremer JM, Bingham CO, 3rd, Cappelli LC, et al : Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs : 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. ACR Open Rheumatol 3 : 173-184, 2021.
PubMed
10) Yun H, Yang S, Chen L, et al : Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases : Implications for Vaccination. Arthritis Rheumatol 68 : 2328-2337. 2016
 
11) Yamaoka K, Tanaka Y, Kameda H, et al : The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf 44 : 711-722, 2021.
PubMed
12) Leung J, Anderson TC, Dooling K, et al : Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults with Immune-Mediated Inflammatory Diseases in the United States. Arthritis Rheumatol 2022. [Online ahead of print]
 
13) Hastie A, Catteau G, Enemuo A, et al : Immunogenicity of the adjuvanted recombinant zoster vaccine : persistence and anamnestic response to additional doses administered 10 years after primary vaccination. J Infect Dis 224 : 2025-2034, 2021.
PubMed
14) Dagnew AF, Rausch D, Herve C, et al : Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases : a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford) 60 : 1226-1233, 2021.
 
15) Yamaoka K, Saharinen P, Pesu M, et al : The Janus kinases (Jaks). Genome Biol 5 : 253, 2004.
PubMed
16) Smolen JS, Aletaha D, Barton A, et al : Rheumatoid arthritis. Nat Rev Dis Primers 4 : 18001, 2018.
PubMed
P.1051 掲載の参考文献
1) Crowson CS, Hoganson DD, Fitz-Gibbon PD, et al : Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 64 (9) : 2847-2855, 2012.
PubMed
2) Doran MF, Crowson CS, Pond GR, et al : Frequency of infection in patients with rheumatoid arthritis compared with controls : a population-based study. Arthritis Rheum 46 (9) : 2287-2293, 2002.
PubMed
3) Winthrop KL, Calabrese LH : Let the fog be lifted : screening for hepatitis B virus before biological therapy. Ann Rheum Dis 70 (10) : 1701-1703, 2011.
PubMed
4) 日本肝臓学会 肝炎診療ガイドライン作成委員会編 : B型肝炎治療ガイドライン (3.4版), 2021年5月. https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/B_v3.4.pdf
 
5) Burton MJ, Curtis JR, Yang S, et al : Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. The Journal of rheumatology 44 (5) : 565-570, 2017.
PubMed
6) Mok CC : Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol 32 (6) : 767-780, 2018.
 
7) Sakai R, Kasai S, Hirano F, et al : No increased risk of herpes zoster in TNF inhibitor and non- TNF inhibitor users with rheumatoid arthritis : epidemiological study using the Japanese health insurance database. Int J Rheum Dis 21 (9) : 1670-1677, 2018.
PubMed
8) Nakajima A, Urano W, Inoue E, et al : Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Mod Rheumatol 25 (4) : 558-561, 2015.
PubMed
9) Harigai M : Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 58 (Suppl 1) : i34-i42, 2019.
 
10) Winthrop KL : The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13 (4) : 234-243, 2017.
PubMed
11) Lal H, Cunningham AL, Godeaux O, et al : Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372 (22) : 2087-2096, 2015.
PubMed
12) Cunningham AL, Lal H, Kovac M, et al : Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 375 (11) : 1019-1032, 2016.
PubMed
13) Yamazaki H, Sakai R, Koike R, et al : Assessment of risks for pulmonary infection during 12 months after commencing or intensifying immunosuppressive treatment for active connective tissue diseases : A report from a large-scale prospective cohort study. J Rheumatol 25 (4) : 609-614, 2014.
 
14) Tanaka M, Sakai R, Koike R, et al : Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors : A Pooled Analysis of 3 Agents. J Rheumatol 42 (9) : 1726-1728, 2015.
PubMed
15) Utsunomiya M, Dobashi H, Odani T, et al : Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases : results from a non-blinded, randomized controlled trial. Arthritis Res Ther 19 (1) : 7, 2017.
 
16) 厚生労働省 : 平成30年 結核登録者情報調査年報集計結果について. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000175095_00002.html
 
17) Yamada T, Nakajima A, Inoue E, et al : Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65 (12) : 1661-1663. 2006
PubMed
18) 日本結核病学会 編 : 結核診療ガイドライン 改訂第3版, 南江堂, 東京, 2015.
 
19) Namkoong H, Kurashima A, Morimoto K, et al : Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis 22 (6) : 1116-1117, 2016.
PubMed
20) Hirose W, Harigai M, Uchiyama T, et al : Low body mass index and lymphocytopenia associate with Mycobacterium avium complex pulmonary disease in patients with rheumatoid arthritis. Mod Rheumatol 29 (1) : 105-112, 2019.
PubMed
21) Hirose W, Uchiyama T, Nemoto A, et al : Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis : results from a cross-sectional observational study. Arthritis Res Ther 17 : 273, 2015.
 
22) Mori S, Tokuda H, Sakai F, et al : Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents : a retrospective multicenter study in Japan. Mod Rheumatol 22 (5) : 727-737, 2012.
PubMed
23) 日本呼吸器学会呼吸器ワクチン検討WG 委員会/日本感染症学会ワクチン委員会・合同委員会 : 65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方 (第3版 2019-10-30). https://www.kansensho.or.jp/uploads/files/guidelines/o65haienV/o65haienV_191030.pdf
 
24) Takeuchi T, Tatsuki Y, Nogami Y, et al : Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67 (2) : 189-194, 2008.
 
25) Koike T, Harigai M, Inokuma S, et al : Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan : interim analysis of 3881 patients. Ann Rheum Dis 70 (12) : 2148-2151, 2011.
PubMed
26) ファイザー株式会社 : リウマトレックスカプセル2mg 適正使用情報 Vol. 27, 2021.
 
27) 日本リウマチ学会MTX 診療ガイドライン策定小委員会 編 : 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2016年改訂版, 羊土社, 東京, 2016.
 
28) 日本呼吸器学会 編 : 薬剤性肺障害の診断・治療の手引き 第2版 2018, メディカルレビュー社, 東京, 2018.
 
29) Mimori T, Harigai M, Atsumi T, et al : Safety and effectiveness of iguratimod in patients with rheumatoid arthritis : Final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol 29 (2) : 314-323, 2019.
PubMed
30) Koike T, Harigai M, Ishiguro N, et al : Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of 7740 patients. Mod Rheumatol 24 (3) : 390-398, 2014.
PubMed
31) Koike T, Harigai M, Inokuma S, et al : Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36 (5) : 898-906, 2009.
PubMed
32) Koike T, Harigai M, Inokuma S, et al : Effectiveness and safety of tocilizumab : postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41 (1) : 15-23, 2014.
PubMed
33) Xie F, Yun H, Bernatsky S, et al : Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 68 (11) : 2612-2617, 2016.
PubMed
34) Kasai S, Sakai R, Koike R, et al : Higher risk of hospitalized infection, cardiovascular disease, and fracture in patients with rheumatoid arthritis determined using the Japanese health insurance database. Mod Rheumatol 29 (5) : 788-794, 2019.
PubMed
35) Michaud K, Berglind N, Franzen S, et al : Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Ann Rheum Dis 75 (10) : 1797-1805, 2016.
PubMed
36) Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al : Risk of incident cardiovascular events in patients with rheumatoid arthritis : a meta-analysis of observational studies. Ann Rheum Dis 71 (9) : 1524-1529, 2012.
PubMed
37) England BR, Thiele GM, Anderson DR, et al : Increased cardiovascular risk in rheumatoid arthritis : mechanisms and implications. BMJ 361 : k1036, 2018.
PubMed
38) Harigai M, Nanki T, Koike R, et al : Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population : a nationwide cohort study in Japan. Mod Rheumatol 26 (5) : 642-650, 2016.
 
39) Harigai M : Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate : A review of the literature and current perspective. Mod Rheumatol 28 (1) : 1-8, 2018.
PubMed
40) Yamada T, Nakajima A, Inoue E, et al : Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int 31 (11) : 1487-1492, 2011.
PubMed
41) Hashimoto A, Chiba N, Tsuno H, et al : Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol 42 (4) : 564-571, 2015.
 
42) Yoshida Y, Takahashi Y, Yamashita H, et al : Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol 24 (5) : 763-765, 2014.
PubMed
43) Jani M, Dixon WG, Chinoy H : Drug safety and immunogenicity of tumour necrosis factor inhibitors : the story so far. Rheumatology (Oxford) 57 (11) : 1896-1907, 2018.
PubMed
44) Kaltsonoudis E, Voulgari PV, Konitsiotis S, et al : Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 13 (1) : 54-58, 2014.
PubMed
45) Kemanetzoglou E, Andreadou E : CNS Demyelination with TNF-alpha Blockers. Curr Neurol Neurosci Rep 17 (4) : 36, 2017.
PubMed
P.1060 掲載の参考文献
1) 桑名正隆 : 高齢者における診断・治療の進歩 : 関節リウマチ. 日内会誌 111 : 454-460, 2022.
 
2) 厚生労働省 難治性疾患政策研究事業 難治性血管炎に関する調査研究班, 日本循環器学会, 日本医学放射線学会, 他 : 血管炎症候群の診療ガイドライン (2017年改訂版), pp.91-95, 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_isobe_h.pdf (2022年5月24日アクセス)
 
3) Miyagawa I, Nakayamada S, Saito K, et al : Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol 24 : 405-409, 2014.
 
4) Nakajima A, Saito K, Kojima T, et al : No increased mortality in patients with rheumatoid arthritis treated with biologics : results from the biologics register of six rheumatology institutes in Japan, Mod Rheumatol 23 : 945-952, 2013.
PubMed
5) Solomon J J, Chung JH, Cosg r ove G, et al : Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 47 : 588-596, 2016.
 
6) Juge PA, Lee JS, Ebstein E, et al : MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 379 : 2209-2219, 2018.
PubMed
7) Hyldgaard C, Hilberg O, Pedersen AB, et al : A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease : comorbidity and mortality. Ann Rheum Dis 76 : 1700-1706, 2017
PubMed
8) 日本呼吸器学会・日本リウマチ学会合同 膠原病に伴う間質性肺疾患診断・治療指針作成委員会 : 膠原病に伴う間質性肺疾患 診断・治療指針 2020, pp.103-113, メディカルレビュー社, 東京, 2020.
 
9) Cottin V, Wollin L, Fischer A, et al : Fibrosing interstitial lung diseases : knowns and unknowns. Eur Respir Rev 28 : 180100, 2019.
PubMed
10) Flaherty KR, Wells AU, Cottin V, et al : Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
11) 桑名正隆 : 膠原病における間質性肺疾患の最新治療. 日内会誌 111 (臨時増刊号) : 90-96, 2022.
 
12) Mimori T, Harigai M, Atsumi T, et al : Safety and effectiveness of iguratimod in patients with rheumatoid arthritis : Final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol 29 : 314-323, 2019.
PubMed
13) Fernandez-Dias C, Loricera J, Castaneda S, et al : Abatacept in patients with rheumatoid arthritis and interstitial lung disease : A national multicenter study of 63 patients. Arthritis Rheum 48 : 22-27, 2018.
 
14) Hozumi H, Nakamura Y, Johkoh T, et al : Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease : a retrospective case control study. BMJ Open 3 : e003132, 2012.
PubMed
15) Perez T, Remy-Jardin M, Cortet B : Airways involvement in rheumatoid arthritis : clinical, functional, and HRCT findings. Am J Respir Crit Care Med 157 : 1658-1665, 1998.
PubMed

【Diagnosis】

P.1070 掲載の参考文献
1) 片山和彦 : ノロウイルス総説 2020. ウイルス 70 (2) : 117-128, 2020.
 
2) Chhabra P, de Graaf M, Parra G I, et al : Updated classification of norovirus genogroups and genotypes. J Gen Virol 100 (10) : 1393-1406, 2019.
PubMed
3) Riordan T, Craske J, Roberts JL, et al : Food borne infection by a Norwalk like virus (small round structured virus). J Clin Pathol 37 (7) : 817-820, 1984.
PubMed
4) 林志直 : ノロウイルス食中毒と感染性胃腸炎. 食品衛生学雑誌 51 (6) : 279-284, 2010.
Medical*Online
5) Robilotti E, Deresinski S, Pinsky BA : Norovirus. Clin Microbiol Rev 28 (1) : 134-164, 2015.
PubMed
6) 白土 (堀越) 東子, 武田直和 : ノロウイルスと血液型抗原. ウイルス 57 (2) : 181-190, 2007.
 
7) Hardy ME, Estes MK : Completion of the Norwalk virus genome sequence. Virus Genes 12 (3) : 287-290, 1996.
PubMed
8) Jiang X, Wang M, Graham DY, et al : Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 66 (11) : 6527-6532, 1992.
 
9) ノロウイルス感染症 2015/16 シーズン. IASR 38 : 1-3, 2017.
 
10) 新規遺伝子型ノロウイルスGII.P17-GII.17の流行. IASR 36 : 175-178, 2015.
 
11) 新型コロナウイルス感染症流行下での宮城県における感染性胃腸炎の流行状況. IASR 42 : 230-232, 2021.
 
12) 感染後のノロウイルス排出期間および排出コピー数. IASR 28 : 286-288, 2007.
 
13) 田中智之, 小林尚明, 豊田茂, 他 : ノロウイルス抗原検出診断薬クイックナビ(TM) -ノロ2の評価. 医学と薬学 68 (6) : 1033-1039, 2012.
Medical*Online
P.1077 掲載の参考文献
1) 島田康司, 皆川温子, 平山由美子, 他 : Real-time-PCR法を用いた, Mycoplasma pneumonia イムノクロマト迅速診断キットに最適な検体採取部位の検討. 日本臨床微生物学雑誌 25 (3) : 196-203, 2015.
 
2) Waites KB, Rikihisa Y, Taylor-Robinson D : Mycoplasma and Ureaplasma. In : Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of Clinical Microbiology 8th Edition. American Society for Microbiology, Washington, DC, pp.972-990, 2003.
 
3) 堀野敦子, 大屋日登美 : 肺炎マイコプラズマの実験室診断. 病原微生物検出情報 33 : 268-269, 2012.
 
4) 「肺炎マイコプラズマ肺炎に対する治療方針」策定委員会 編 : 肺炎マイコプラズマ肺炎に対する治療指針, pp.7-8, 日本マイコプラズマ学会, 2014.
 
5) Jonas M W, Kathleen A T, Stephanie L M, et al : Evaluation of Three Real-Time PCR Assays for Detection of Mycoplasma pneumoniae in an Outbreak Investigation. J Clin Microbiol 46 (9) : 3116-3118, 2008.
 
P.1086 掲載の参考文献
1) Kahaly GJ, Diana T, Olivo PD : TSH Receptor antibodies : Relevance & Utility. Endocr Pract 26 (1) : 97-106, 2020.
PubMed
2) Kamijo K, Togashi K : Development of More Sensitive Bioassay of TSAb Due to the Modification of Conventional Assay and its Measurement in M22-TRAb-Seronegative Graves'Patients. Annals Thyroid Res 1 (1) : 5-10, 2014.
 
3) 上條桂一, 村山寛, 富樫和美 : ブタ甲状腺細胞を用いたTSAbバイオアッセイ改良法. 医学と薬学 71 (5) : 903-911, 2014.
Medical*Online
4) 上條桂一 : TSAb (EIA) 測定の臨床応用. 日本甲状腺学会雑誌 9 (9) : 166-171, 2018.
Medical*Online
P.1094 掲載の参考文献
1) Adams D D, Purves H D : ABNORMAL RESPONSES IN THE ASSAY OF THYROTROPHIN. Proc Univ Otago Med School 34 : 11, 1956.
 
2) Adams D D, Kenndy T H : Occurrence in Thyrotoxicosis of a Gamma Globulin Which Protects LATS from Neutralization by an Extract of Thyroid Gland. J Clin Endocrinol Metab 27 : 173, 1967.
 
3) Smith B R, Hall R : THYROID-STIMULATING IMMUNOGLOBULINS IN GRAVES' DISEASE. Lancet 2 : 427, 1974.
PubMed
4) Endo K, Borges M, Amir S, et al : Preparation of 12'1-Labeled Receptor-Purified Graves' Immunoglobulins : Properties of Their Binding to Human Thyroid Membranes. J Clin Endocrinol Metab 55 : 566, 1982.
 
5) Tozzoli R, Kodermaz G, Villalta D, et al : Accuracy of receptor-based methods for detection of thyrotropin-receptor autoantibodies : a new automated third-generation immunoassay shows higher analytical and clinical sensitivity for the differential diagnosis of hyperthyroidism. Auto Immun High-lights 1 : 95-100, 2010.
 
6) Onaya T, Kotani M, Yamada T, et al : New in Vitro Tests to Detect the Thyroid Stimulator in Sera from Hyperthyroid Patients by Measuring Colloid Droplet Formation and Cyclic AMP in Human Thyroid Slices. J Clin Endocrinol Metab 36 : 859, 1973.
PubMed
7) Orgiazzi J, Williams E D, Chopra J I, et al : Human Thyroid Adenyl Cyclase-Stimulating Activity in Immunoglobulin G of Patients with Graves' Disease. J Clin Endocrinol Metab 42 : 341, 1976.
 
8) Kasagi K, Konishi J, Iida Y, et al : A New in Vitro Assay for Human Thyroid Stimulator Using Cultured Thyroid Cells : Effect of Sodium Chloride on Adenosine 3,5'- Monophosphate Increase. J Clin Endocrinol Metab 54 : 108, 1982.
PubMed
9) Kasagi K, Konishi J, Iida Y, et al : A Sensitive and Practical Assay for Thyroid-Stimulating Antibodies Using Crude Immunoglobulin Fractions Precipitated with Polyethylene Glycol. J Clin Endocrinol Metab 62 : 855, 1986.
PubMed
10) Kasagi K, Konishi J, Iida Y, et al : A sensitive and practical assay for thyroid-stimulating antibodies using FRTL-5 thyroid cells. Acta Endocrinol 115 : 30, 1987.
PubMed
11) 上條桂一, 村山寛, 富樫和美 : ブタ甲状腺細胞を用いたTSAbバイオアッセイ改良法の基礎的・臨床的研究. 医学と薬学 71 (5) : 903-911, 2014.
Medical*Online
12) 上條桂一 : TSAb (EIA) 測定の臨床応用. 日本甲状腺学会雑誌 9 : 166-171, 2018.
Medical*Online
P.1107 掲載の参考文献
1) CDI診療ガイドライン作成委員会 : Clostridioides (Clostridium) difficile感染症診療ガイドライン, 2018.
 
2) 豊川真弘 : Clostridioides difficile. 臨床と微生物 45 (3) : 209-214, 2018.
Medical*Online
3) 村端真由美, 加藤はる, 矢野久子, 他 : 長期入院がん患児におけるClostridium difficile消化管保有と院内伝播に関する検討. 感染症誌 82 : 419-426, 2008.
 
4) L Clifford McDonald, George E Killgore, Angela Thompson, et al : An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 (23) : 2433-2441, 2005.
PubMed
5) Dena Lyras, Jennifer R O'Connor, Pauline M Howarth, et al : Toxin B is essential for virulence of Clostridium difficile. Nature 458 : 1176-1179, 2009.
 
6) Monot M, Eckert C, Lemire A, et al : Clostridium difficile : New Insights into the Evolution of the Pathogenicity Locus. Sci Rep 5 : 15023, 2015.
PubMed
7) 加藤はる, 妹尾充敏 : 日本のClostridioides difficile感染症の分子疫学. 日本臨床微生物学会雑誌 31 (2) : 66-74, 2021.
 
8) 松浦成美, 佐伯裕二, 梅木一美, 他 : C. DIFF QUIK CHEK COMPLETE(R) にてクロストリジウム・ディフィシル抗原 (グルタミン酸デヒドロゲナーゼ (GDH)) 陽性・トキシン陰性を示した検体におけるBD マックスCDIFF(R) を用いた遺伝子検査の有用性. 医学検査 67 (4) : 451-455, 2018.
Medical*Online
9) 大野真依, 木部泰志, 清祐麻紀子, 他 : Clostridioides difficile 感染症診断におけるXpert C. difficileの性能評価. 医学検査 70 (2) : 286-290, 2021.
Medical*Online
10) 加藤はる : Clostridioides difficile細菌学的検査について押さえておくべきポイント. medicina 56 (12) : 1988-1992, 2019.
 
11) 澤辺悦子, 北村優佳, 古畑紀子, 他 : Clostridium difficile感染症の迅速診断における糞便中C. difficile抗原およびトキシンA/B同時検出キット : C. DIFF QUIK CHEK COMPLETEの有用性に関する検討. 日本臨床微生物学会雑誌 21 (4) : 253-259, 2011
 
12) 谷野洋子, 木村武史, 牛山正二, 他 : Toxigenic cultureを用いた毒素産生Clostridium difficile検出の基礎的検討. 医学検査 64 (6) : 680-685, 2015.
Medical*Online
13) 谷野洋子, 児玉真衣, 大長洋臣, 他 : 2-Step Methodによる毒素産生Clostridium difficile検出のための検査方法の選択. 臨床微生物迅速診断研究会誌 27 (1) : 9-14, 2017.
Medical*Online
14) 原稔典, 鈴木広道, 大柳忠智, 他 : 便培養コロニーを用いたClostridioides difficile特異抗原および毒素検出におけるC. DIFF QUIK CHEKコンプリートの多施設臨床性能評価. 日本臨床微生物学会雑誌 31 (3) : 38-43, 2021.
 
15) 吉田賢太 : Clostridioides difficile抗原迅速診断キット「クイックチェイサー(R) CD GDH/TOX」の有用性に関する評価. 医学と薬学 78 (5) : 633-641, 2021.
Medical*Online
16) アボット ダイアグノスティクス メディカル株式会社 : C. DIFF QUIK CHEK コンプリート 添付文書 (第10版)
 
17) 株式会社ミズホメディー : クイックチェイサーCD GDH/TOX 添付文書 (第5版)
 
18) Hiroyuki Kubota, Takafumi Sakai, Agata Gawad : Development of TaqMan-Based Quantitative PCR for Sensitive and Selective Detection of Toxigenic Clostridium difficile in Human Stools. PLOS ONE 9 (10) : 1-10, 2014.
PubMed
P.1116 掲載の参考文献
1) 日本TDM学会 : 2015年度版 循環器薬の薬物血中濃度モニタリングに関するガイドライン, 2015.
 
2) Jusko WJ, Thomson AW, Fung J, et al : Consensus document : therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 17 : 606-614, 1995.
PubMed
3) Oellerich M, Armstrong VW, Schutz E, et al : Therapeutic drug monitoring of cyclosporine and tacrolimus. Clin Biochem 31 : 309-316, 1998.
PubMed
4) Nishizono I, Iida S, Suzuki N, et al : Rapid and Sensitive Chemiluminescent Enzyme Immunoassay for Measuring Tumor Markers. Clin Chem 37 : 1639-1644, 1991.
PubMed
5) Clinical and Laboratory Standards Institute. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures ; Approved Guideline-Second Edition. CLSI Document EP17-A2.
 
6) 三浦昌朋, 増田智先, 江川裕人, 他 : Interhospital laboratory variability and the imprecision of current immunoassay methods for tacrolimus from iMPT.
 

【症例報告】

P.1121 掲載の参考文献
1) Yoon-Jin Kim, et al : Conditioned media from human umbilical cord blood-derived mesenchymal stem cells stimulate rejuvenation function in human skin. Biochem Biophys Rep 16 : 96-102, 2018.
PubMed

書評

最近チェックした商品履歴

Loading...